Full video transcriptClick to expand
Auto-generated transcript of @d4navar's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00It really is over around three months. I gained about 15 kgs, stayed lean, didn't really give me moon face or anything like that.
- 0:08I prefer it way over MK for the fact that there's a bunch of hype around MK. People don't know the long-term effects and it's a tablet
- 0:16injectables all the way because it's healthier for you in the long run for your liver.
- 0:21And it'd be surprised how strong it is for appetite. It's very strong. I can pin it and probably get around 5k calories down me.
- 0:29And around two hours.
GHRP-6 vs MK-677: what the evidence actually says
Quick answer
GHRP-6 is a ghrelin-receptor agonist that stimulates pulsatile GH release and carries a documented appetite-stimulating effect via hypothalamic signaling, but it also transiently elevates cortisol and prolactin. The creator's comparison to MK-677 is based on a mischaracterization of hepatic metabolism, since neither compound's safety profile is primarily determined by its route of administration. Neither GHRP-6 nor MK-677 has regulatory approval for body composition purposes, and long-term human safety data for both compounds remains limited.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GHRP-6 vs MK-677: what the evidence actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
GHRP-6 vs MK-677: what the evidence actually says should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GHRP-6 vs MK-677: what the evidence actually says" from d4navar. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GHRP-6 is a ghrelin-receptor agonist that stimulates pulsatile GH release and carries a documented appetite-stimulating effect via hypothalamic signaling, but it also transiently elevates cortisol and prolactin.
The reason this review is not generic is the source wording and the canonical claim label "peptides replying to anabolictemple ghrp6 mk all the way fyp ascend g." In this clip, the useful excerpt is: "It really is over around three months." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GHRP-6 is a ghrelin-receptor agonist that stimulates pulsatile GH release and carries a documented appetite-stimulating effect via hypothalamic signaling, but it also transiently elevates cortisol and prolactin.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GHRP-6 is a ghrelin-receptor agonist that stimulates pulsatile GH release and carries a documented appetite-stimulating effect via hypothalamic signaling, but it also transiently elevates cortisol and prolactin. The creator's comparison to MK-677 is based on a mischaracterization of hepatic metabolism, since neither compound's safety profile is primarily determined by its route of administration. Neither GHRP-6 nor MK-677 has regulatory approval for body composition purposes, and long-term human safety data for both compounds remains limited.
- GHRP-6 binds GHSR-1a ghrelin receptors and produces measurable GH pulses, confirmed in human studies since Bowers et al. (1991, JCEM), but it is not FDA-approved for body composition use.
- The claim that injectables are easier on the liver than tablets is not a pharmacological rule. GHRP-6 is broken down by proteases, not liver enzymes, but that reflects its peptide chemistry, not its injection route.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GHRP-6 binds GHSR-1a ghrelin receptors and produces measurable GH pulses, confirmed in human studies since Bowers et al. (1991, JCEM), but it is not FDA-approved for body composition use.
- The claim that injectables are easier on the liver than tablets is not a pharmacological rule. GHRP-6 is broken down by proteases, not liver enzymes, but that reflects its peptide chemistry, not its injection route.
- GHRP-6 stimulates cortisol and prolactin alongside GH (Arvat et al., 1997, JCEM), meaning it is not free of hormonal side effects, including those that could theoretically contribute to facial puffiness.
- MK-677's longest controlled human trial is approximately two years (Nass et al., 2008, JCEM). Long-term safety data for GHRP-6 in healthy adults used for body composition is similarly limited.
- The FDA removed GHRP-6 from the 503A bulk compounding list in 2023, meaning it cannot legally be compounded for most clinical uses in the United States.
- A 15 kg lean gain in 90 days exceeds outcomes seen in controlled GH-axis research, including in GH-deficient populations receiving actual GH replacement therapy.
- Acute appetite stimulation from GHRP-6 is pharmacologically real, but using that effect to sustain a large caloric surplus carries its own metabolic risks that are not addressed in this video.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @d4navar actually say?
@d4navar claims that over roughly three months on GHRP-6, they gained about 15 kg while staying lean, avoided the puffy "moon face" side effect, and found the appetite stimulation so strong they could eat around 5,000 calories within two hours of pinning. They also argue that GHRP-6 is healthier than MK-677 specifically because it is injectable rather than oral, sparing the liver from the stress of a tablet compound. Their overall take: GHRP-6 beats MK-677, full stop.
That is a lot of ground to cover in a short video, and some of it is defensible, some of it is oversimplified, and at least one part of it is physiologically backwards.
Does the science back this up?
Partially. GHRP-6 is a synthetic hexapeptide that stimulates ghrelin receptors, triggering a pulse of endogenous growth hormone release. Its appetite effects are real and well-documented. The liver-safety argument, though, does not hold up the way the creator frames it.
GHRP-6 binds ghrelin receptors (GHSR-1a) and produces measurable GH pulses, confirmed in human studies going back to Bowers et al. (1991, Journal of Clinical Endocrinology and Metabolism). The appetite stimulation is driven by the same ghrelin-receptor pathway that signals hunger in the hypothalamus, which explains why the creator's calorie intake reportedly spiked sharply post-injection. That part is biologically plausible.
MK-677 (ibutamoren) is an orally active GH secretagogue that works through the same receptor class. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) showed it produced sustained GH and IGF-1 elevation over 12 months in healthy older adults. Both compounds carry real risk profiles. Neither has FDA approval for the uses discussed here.
What did they get wrong (or right)?
The "injectables are healthier for your liver" claim is the most clearly wrong thing in this video. MK-677 does undergo hepatic metabolism, but GHRP-6 is a peptide broken down by proteases, not liver enzymes, so framing the comparison as "injection equals liver-safe" misrepresents how drug metabolism actually works. The route of administration does not automatically determine hepatotoxicity risk.
The "moon face" claim deserves nuance. Moon face is typically associated with excess cortisol, not GH secretagogues directly. GHRP-6 does stimulate cortisol and prolactin release alongside GH, documented by Arvat et al. (1997, Journal of Clinical Endocrinology and Metabolism). Whether someone experiences visible cortisol-related changes depends on dose, individual response, and duration, not simply which compound they chose.
Where the creator earns some credit: the concern about unknown long-term effects of MK-677 is legitimate. The longest controlled human trial runs about two years, and the compound was abandoned by Merck before approval. Skepticism about hype around MK-677 is reasonable, even if the reasoning offered here is shaky.
What should you actually know?
GHRP-6 and MK-677 are both experimental compounds in the context of body composition. Neither is approved by the FDA for muscle gain, fat loss, or recovery in healthy adults. GHRP-6 is not legally available as a compounded product for general use in the US since the FDA removed it from the permissible compounding list in 2023.
A 15 kg lean gain in three months would represent an extraordinary outcome that exceeds what controlled GH-secretagogue research has produced. Johannsson et al. (1997, Journal of Clinical Endocrinology and Metabolism) found modest lean mass changes with genuine GH replacement therapy in deficient adults, far below those numbers. The claim is not impossible if the individual was in a significant caloric surplus, was a newer trainee, or used additional compounds not mentioned, but presenting it as a product of GHRP-6 alone is misleading.
Anyone considering peptide therapy should have a formal clinical evaluation, including IGF-1 baseline, before pursuing GH-axis compounds. Self-administered, unmonitored use carries real risks including insulin resistance, fluid retention, and cortisol dysregulation.
Bottom line
@d4navar's video reflects a real-world user experience, not a clinical trial. The appetite effects they describe are pharmacologically plausible. The liver-safety argument is wrong. The 15 kg lean claim is extraordinary and unsupported by the broader evidence. Treat this as one person's anecdote, not a protocol.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
d4navar · TikTok creator
6.2K views on this video
Replying to @anabolictemple ghrp6>>>mk all the way ‼️#fyp #ascend #gh #gymtok
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about ghrp-6 binds ghsr-1a ghrelin receptors?
GHRP-6 binds GHSR-1a ghrelin receptors and produces measurable GH pulses, confirmed in human studies since Bowers et al. (1991, JCEM), but it is not FDA-approved for body composition use.
What does the video say about the claim?
The claim that injectables are easier on the liver than tablets is not a pharmacological rule. GHRP-6 is broken down by proteases, not liver enzymes, but that reflects its peptide chemistry, not its injection route.
What does the video say about ghrp-6 stimulates cortisol?
GHRP-6 stimulates cortisol and prolactin alongside GH (Arvat et al., 1997, JCEM), meaning it is not free of hormonal side effects, including those that could theoretically contribute to facial puffiness.
What does the video say about mk-677's longest controlled human trial?
MK-677's longest controlled human trial is approximately two years (Nass et al., 2008, JCEM). Long-term safety data for GHRP-6 in healthy adults used for body composition is similarly limited.
What does the video say about the fda removed ghrp-6 from the 503a bulk compounding list?
The FDA removed GHRP-6 from the 503A bulk compounding list in 2023, meaning it cannot legally be compounded for most clinical uses in the United States.
What does the video say about a 15 kg lean gain in 90 days exceeds outcomes?
A 15 kg lean gain in 90 days exceeds outcomes seen in controlled GH-axis research, including in GH-deficient populations receiving actual GH replacement therapy.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by d4navar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.